Keyword: Illumina

Inscripta aims to broaden access to CRISPR by offering new enzymes for free, and to boost R&D by outfitting scientists with a full suite of tools.

Illumina received its first official approval in China for its MiSeqDx benchtop sequencer, allowing it to directly market NGS testing in the country.

Just two weeks after Bionano Genomics filed to raise up to $30 million in its Nasdaq IPO, the company is cutting it to $16 million.

Growing demand for genomic sequencing drove Illumina to record profits, boosting the company’s stock price by over 7% in premarket trading.

One of the founding scientists of Illumina has come out with a new gene-sequencing software startup that aims to tackle antimicrobial resistance.

Helix is expanding its senior leadership team and acquiring app developer HumanCode, adding momentum after a planned $200 million VC round.

Merck paired up with Foundation Medicine to develop a pan-cancer diagnostic for Keytruda to measure microsatellite instability and other biomarkers.

Grail has gone 3-for-3 in venture capital rounds topping $100 million—with a $300 million addition bringing its total up to $1.5 billion since 2016.

Illumina has bought Edico Genome and its Dragen next-generation sequencing and data analysis platform. The terms of the deal were not disclosed.

The round moves 10x’s VC haul up past the $180 million mark, setting it up to introduce a range of add-ons to its core technology in the coming months.